Poseida Therapeutics, Inc. (PSTX) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Poseida Therapeutics, Inc. (PSTX) Bundle
Looking to evaluate the intrinsic value of Poseida Therapeutics, Inc.? Our PSTX DCF Calculator incorporates real-world data along with extensive customization features, allowing you to refine your forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | 130.4 | 64.7 | 72.7 | 81.8 | 91.9 | 103.3 | 116.1 |
| Revenue Growth, % | 0 | 0 | 0 | 417217.08 | -50.37 | 12.41 | 12.41 | 12.41 | 12.41 | 12.41 |
| EBITDA | -91.7 | -145.5 | -117.1 | -54.8 | -109.0 | -6.1 | -6.9 | -7.7 | -8.7 | -9.8 |
| EBITDA, % | 100 | 100 | -374748.7 | -42.02 | -168.52 | -8.4 | -8.4 | -8.4 | -8.4 | -8.4 |
| Depreciation | 1.2 | 2.6 | 4.6 | 5.2 | 5.6 | 45.5 | 51.1 | 57.5 | 64.6 | 72.6 |
| Depreciation, % | 100 | 100 | 14572 | 3.97 | 8.68 | 62.53 | 62.53 | 62.53 | 62.53 | 62.53 |
| EBIT | -92.9 | -148.1 | -121.6 | -59.9 | -114.7 | -6.7 | -7.5 | -8.5 | -9.5 | -10.7 |
| EBIT, % | 100 | 100 | -389320.7 | -45.98 | -177.2 | -9.2 | -9.2 | -9.2 | -9.2 | -9.2 |
| Total Cash | 125.3 | 309.2 | 206.3 | 282.5 | 212.2 | 72.7 | 81.8 | 91.9 | 103.3 | 116.1 |
| Total Cash, percent | .0 | .0 | .7 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | 9.1 | 9.0 | 32.1 | 36.1 | 40.6 | 45.6 | 51.3 |
| Account Receivables, % | 100 | 100 | 0 | 6.97 | 13.93 | 44.18 | 44.18 | 44.18 | 44.18 | 44.18 |
| Inventories | .0 | .0 | .0 | 4.5 | .0 | 29.6 | 33.3 | 37.4 | 42.0 | 47.2 |
| Inventories, % | 100 | 100 | 0 | 3.42 | 0 | 40.68 | 40.68 | 40.68 | 40.68 | 40.68 |
| Accounts Payable | 4.9 | .8 | 9.0 | 2.2 | 3.3 | 44.6 | 50.2 | 56.4 | 63.4 | 71.2 |
| Accounts Payable, % | 100 | 100 | 28686.22 | 1.71 | 5.05 | 61.35 | 61.35 | 61.35 | 61.35 | 61.35 |
| Capital Expenditure | -5.2 | -16.9 | -2.6 | -3.9 | -3.1 | -15.7 | -17.6 | -19.8 | -22.3 | -25.0 |
| Capital Expenditure, % | 100 | 100 | -8432.04 | -3.01 | -4.74 | -21.55 | -21.55 | -21.55 | -21.55 | -21.55 |
| Tax Rate, % | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 |
| EBITAT | -99.4 | 2,798.2 | 4,285.5 | -60.5 | -114.8 | -4.0 | -4.5 | -5.1 | -5.7 | -6.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -98.5 | 2,779.7 | 4,295.7 | -79.5 | -106.6 | 14.4 | 26.9 | 30.2 | 34.0 | 38.2 |
| WACC, % | 7.27 | 6.34 | 6.34 | 7.27 | 7.27 | 6.9 | 6.9 | 6.9 | 6.9 | 6.9 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 115.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 39 | |||||||||
| Terminal Value | 795 | |||||||||
| Present Terminal Value | 569 | |||||||||
| Enterprise Value | 684 | |||||||||
| Net Debt | 41 | |||||||||
| Equity Value | 643 | |||||||||
| Diluted Shares Outstanding, MM | 90 | |||||||||
| Equity Value Per Share | 7.13 |
What You Will Get
- Comprehensive PSTX Financials: Access to both historical and projected data for precise valuation.
- Customizable Inputs: Adjust discount rates, tax implications, revenue forecasts, and capital investments.
- Real-Time Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Poseida's future growth potential.
- User-Friendly Interface: Designed for industry professionals while remaining easy for newcomers.
Key Features
- Real-Life PSTX Data: Pre-filled with Poseida Therapeutics’ historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- Step 1: Download the Excel file for Poseida Therapeutics, Inc. (PSTX).
- Step 2: Review Poseida's pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify assumptions.
- Step 5: Evaluate the outputs and leverage the results for investment strategies.
Why Choose Poseida Therapeutics, Inc. (PSTX)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Strong Pipeline: A diverse range of product candidates targeting various cancers and genetic diseases.
- Expert Team: Led by industry veterans with extensive experience in biotechnology and pharmaceuticals.
- Commitment to Quality: Rigorous research and development processes ensure high standards of safety and efficacy.
- Collaborative Partnerships: Strategic alliances with leading organizations enhance development capabilities.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for analyzing investments in Poseida Therapeutics, Inc. (PSTX).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Offer clients precise valuation insights related to Poseida Therapeutics, Inc. (PSTX).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotechnology companies like Poseida Therapeutics, Inc. (PSTX) are valued in the market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Poseida Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Poseida Therapeutics, Inc. (PSTX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.